Golden Meditech Announces the Condition to the Voluntary Conditional Cash Offer Has Been Satisfied

Wednesday, March 15, 2017 General News J E 4

HONG KONG, March 15, 2017 /PRNewswire/ -- Golden Meditech Holdings Limited (SEHK stock code: 00801, TWSE stock code: 910801) ("Golden Meditech" or the "Company"), a leading integrated healthcare enterprise in China, today announced that the shareholding ratio condition to the voluntary conditional cash offer made by Mr. Kam Yuen, the Chairman, executive director and controlling shareholder of the Company, through his controlled company -- Magnum Opus 3 International Holdings Limited ("MO3") has been satisfied, as a result, the voluntary conditional cash offer is now unconditional.

As of today, valid acceptances of the cash offer have been received in respect of 460,817,868 shares (representing approximately 15.54% of the issued share capital and voting rights of the Company). Consequently, together with the abovementioned share offer acceptances, MO3 and its concert parties would hold an aggregate of 1,579,087,394 shares, representing approximately 53.24% of the issued share capital and voting rights of the Company.

The cash offer will remain open for acceptance until the final closing date, which is at 4 p.m. on 10 April 2017. Shareholders of the Company who wish to accept the offer are advised to complete the relevant procedures on or before the final closing date.

Details of the acceptance of the voluntary conditional cash offer have been published by the Company in accordance with the Rules Governing the Listing of Securities on the Stock Exchange of Hong Kong Limited and posted on the Company's website as follows:

About Golden Meditech Holdings Limited (SEHK stock code: 00801, TWSE stock code: 910801)

Golden Meditech ( is a leading integrated-healthcare enterprise in China. It is a first-mover in China, having established its dominant positions in several markets including the medical devices market, the cord blood storage market and the hospital management market in the healthcare industry, thanks to its strengths in innovation and market expertise and the ability to capture emerging market opportunities. Going forward, Golden Meditech will continue to pursue a leading position in China's healthcare industry both through organic growth and strategic expansion.

To view the original version on PR Newswire, visit:

SOURCE Golden Meditech Holdings Limited



You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
Cannabis Companies Continue to Invest in Infrastru...
CRH Medical Corporation Announces Acquisition in F...